Lung Transplant Lifts 1-Year Survival to 100% in Selected Stage IV NSCLC Patients
Updated
Updated · Medical Dialogues · Aug 19
Lung Transplant Lifts 1-Year Survival to 100% in Selected Stage IV NSCLC Patients
3 articles · Updated · Medical Dialogues · Aug 19
Summary
A prospective single-center study found 17 selected stage IV NSCLC patients who received lung transplants had 100% estimated 1-year survival, versus 40.8% for 81 similar patients treated with medical management alone.
The benefit appeared in patients whose cancer remained confined to the lungs but had caused medically refractory respiratory failure, a group that often dies from progressive respiratory failure.
Among 306 transplant recipients without cancer, 1-year post-transplant survival was 88.1%, compared with 100% in the NSCLC transplant group, suggesting early organ-use outcomes were not worse in the cancer cohort.
By extended follow-up through Jan. 31, 2026, two transplanted NSCLC patients had died, and the authors said longer-term survival and quality-of-life data are still needed before broader adoption.